Details of the Drug

General Information of Drug (ID: DMZIQ8G)

Drug Name
Prolarix
Synonyms Prolarix (TN)
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 181.19
Logarithm of the Partition Coefficient (xlogp) -1.1
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
Chemical Identifiers
Formula
C8H11N3O2
IUPAC Name
1-(2-amino-2-oxoethyl)-4H-pyridine-3-carboxamide
Canonical SMILES
C1C=CN(C=C1C(=O)N)CC(=O)N
InChI
InChI=1S/C8H11N3O2/c9-7(12)5-11-3-1-2-6(4-11)8(10)13/h1,3-4H,2,5H2,(H2,9,12)(H2,10,13)
InChIKey
WEJRSYKFMCUCRQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
403128
CAS Number
64881-21-6
TTD ID
D0C6VV

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Quinone reductase 2 (NQO2) TTJLP0R NQO2_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00746590) Study of Anti-tumour Effects and Safety of Prolarix in Hepatocellular Carcinoma. U.S. National Institutes of Health.
2 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.